Treatment of chronic hepatitis C in Europe

Massimo Colombo, Maria Grazia Rumi, Ersilio Del Ninno

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The lifetime cumulative risk of developing cirrhosis and hepatocellular carcinoma is the rationale for treating patients with chronic hepatitis C with antivirals. The standard treatment is combination therapy with interferon-alfa and ribavirin. In patients with high transaminases and histologic signs of chronic hepatitis, 6- to 12-month therapy with 3 mega units (MU) interferon-alfa thrice weekly, combined with ribavirin, yielded up to 30% sustained responders, and this was increased to 50% with pegylated interferon combined with ribavirin. Favorable predictors of response to the former treatment were genotype 2 or 3, less than 2 million copies of hepatitis C virus (HCV), no portal fibrosis at biopsy, age less than 40 years, and female sex. The same was true for the latter treatment; however, with body weight less than 82kg replacing female sex. A 98% cure of community-acquired acute hepatitis C was achieved with early treatment with daily doses of 5MU interferon, compared with a calculated 30% HCV-RNA clearance in untreated patients. More cost-effective strategies for ceasing treatment, based upon early clearance of HCV, are under investigation, with cutoff equal to or more than a 2 log decrease in serum HCV-RNA at week 12. This approach has 100% negative predictive value and 80% positive predictive value. Treatment can also be optimized by combination retreatment of relapsers and nonresponders to monotherapy, which yielded sustained responses of 50% and 25%, respectively. There are difficult-to-treat patients who have high viremia, genotype 1 and 4, or coinfection with HIV or HBV, or carry an organ graft, and those who did not respond to combination therapy. Extended treatment of the latter patients with pegylated interferon might slow down the progression of fibrosis.

Original languageEnglish
Pages (from-to)168-171
Number of pages4
JournalJournal of Hepato-Biliary-Pancreatic Surgery
Volume10
Issue number2
DOIs
Publication statusPublished - 2003

Fingerprint

Chronic Hepatitis C
Hepacivirus
Ribavirin
Interferons
Therapeutics
Fibrosis
Interferon-alpha
Genotype
RNA
Retreatment
Viremia
Chronic Hepatitis
Hepatitis C
Transaminases
Coinfection
Antiviral Agents
Hepatocellular Carcinoma
Body Weight
HIV
Transplants

Keywords

  • Chronic hepatitis C
  • Combination therapy
  • Interferon
  • Pegylated interferon

ASJC Scopus subject areas

  • Surgery

Cite this

Treatment of chronic hepatitis C in Europe. / Colombo, Massimo; Rumi, Maria Grazia; Del Ninno, Ersilio.

In: Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 10, No. 2, 2003, p. 168-171.

Research output: Contribution to journalArticle

Colombo, Massimo ; Rumi, Maria Grazia ; Del Ninno, Ersilio. / Treatment of chronic hepatitis C in Europe. In: Journal of Hepato-Biliary-Pancreatic Surgery. 2003 ; Vol. 10, No. 2. pp. 168-171.
@article{938e8cf39d0d4603917bb7437207cd8d,
title = "Treatment of chronic hepatitis C in Europe",
abstract = "The lifetime cumulative risk of developing cirrhosis and hepatocellular carcinoma is the rationale for treating patients with chronic hepatitis C with antivirals. The standard treatment is combination therapy with interferon-alfa and ribavirin. In patients with high transaminases and histologic signs of chronic hepatitis, 6- to 12-month therapy with 3 mega units (MU) interferon-alfa thrice weekly, combined with ribavirin, yielded up to 30{\%} sustained responders, and this was increased to 50{\%} with pegylated interferon combined with ribavirin. Favorable predictors of response to the former treatment were genotype 2 or 3, less than 2 million copies of hepatitis C virus (HCV), no portal fibrosis at biopsy, age less than 40 years, and female sex. The same was true for the latter treatment; however, with body weight less than 82kg replacing female sex. A 98{\%} cure of community-acquired acute hepatitis C was achieved with early treatment with daily doses of 5MU interferon, compared with a calculated 30{\%} HCV-RNA clearance in untreated patients. More cost-effective strategies for ceasing treatment, based upon early clearance of HCV, are under investigation, with cutoff equal to or more than a 2 log decrease in serum HCV-RNA at week 12. This approach has 100{\%} negative predictive value and 80{\%} positive predictive value. Treatment can also be optimized by combination retreatment of relapsers and nonresponders to monotherapy, which yielded sustained responses of 50{\%} and 25{\%}, respectively. There are difficult-to-treat patients who have high viremia, genotype 1 and 4, or coinfection with HIV or HBV, or carry an organ graft, and those who did not respond to combination therapy. Extended treatment of the latter patients with pegylated interferon might slow down the progression of fibrosis.",
keywords = "Chronic hepatitis C, Combination therapy, Interferon, Pegylated interferon",
author = "Massimo Colombo and Rumi, {Maria Grazia} and {Del Ninno}, Ersilio",
year = "2003",
doi = "10.1007/s00534-002-0728-4",
language = "English",
volume = "10",
pages = "168--171",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "0944-1166",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Treatment of chronic hepatitis C in Europe

AU - Colombo, Massimo

AU - Rumi, Maria Grazia

AU - Del Ninno, Ersilio

PY - 2003

Y1 - 2003

N2 - The lifetime cumulative risk of developing cirrhosis and hepatocellular carcinoma is the rationale for treating patients with chronic hepatitis C with antivirals. The standard treatment is combination therapy with interferon-alfa and ribavirin. In patients with high transaminases and histologic signs of chronic hepatitis, 6- to 12-month therapy with 3 mega units (MU) interferon-alfa thrice weekly, combined with ribavirin, yielded up to 30% sustained responders, and this was increased to 50% with pegylated interferon combined with ribavirin. Favorable predictors of response to the former treatment were genotype 2 or 3, less than 2 million copies of hepatitis C virus (HCV), no portal fibrosis at biopsy, age less than 40 years, and female sex. The same was true for the latter treatment; however, with body weight less than 82kg replacing female sex. A 98% cure of community-acquired acute hepatitis C was achieved with early treatment with daily doses of 5MU interferon, compared with a calculated 30% HCV-RNA clearance in untreated patients. More cost-effective strategies for ceasing treatment, based upon early clearance of HCV, are under investigation, with cutoff equal to or more than a 2 log decrease in serum HCV-RNA at week 12. This approach has 100% negative predictive value and 80% positive predictive value. Treatment can also be optimized by combination retreatment of relapsers and nonresponders to monotherapy, which yielded sustained responses of 50% and 25%, respectively. There are difficult-to-treat patients who have high viremia, genotype 1 and 4, or coinfection with HIV or HBV, or carry an organ graft, and those who did not respond to combination therapy. Extended treatment of the latter patients with pegylated interferon might slow down the progression of fibrosis.

AB - The lifetime cumulative risk of developing cirrhosis and hepatocellular carcinoma is the rationale for treating patients with chronic hepatitis C with antivirals. The standard treatment is combination therapy with interferon-alfa and ribavirin. In patients with high transaminases and histologic signs of chronic hepatitis, 6- to 12-month therapy with 3 mega units (MU) interferon-alfa thrice weekly, combined with ribavirin, yielded up to 30% sustained responders, and this was increased to 50% with pegylated interferon combined with ribavirin. Favorable predictors of response to the former treatment were genotype 2 or 3, less than 2 million copies of hepatitis C virus (HCV), no portal fibrosis at biopsy, age less than 40 years, and female sex. The same was true for the latter treatment; however, with body weight less than 82kg replacing female sex. A 98% cure of community-acquired acute hepatitis C was achieved with early treatment with daily doses of 5MU interferon, compared with a calculated 30% HCV-RNA clearance in untreated patients. More cost-effective strategies for ceasing treatment, based upon early clearance of HCV, are under investigation, with cutoff equal to or more than a 2 log decrease in serum HCV-RNA at week 12. This approach has 100% negative predictive value and 80% positive predictive value. Treatment can also be optimized by combination retreatment of relapsers and nonresponders to monotherapy, which yielded sustained responses of 50% and 25%, respectively. There are difficult-to-treat patients who have high viremia, genotype 1 and 4, or coinfection with HIV or HBV, or carry an organ graft, and those who did not respond to combination therapy. Extended treatment of the latter patients with pegylated interferon might slow down the progression of fibrosis.

KW - Chronic hepatitis C

KW - Combination therapy

KW - Interferon

KW - Pegylated interferon

UR - http://www.scopus.com/inward/record.url?scp=0141702081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141702081&partnerID=8YFLogxK

U2 - 10.1007/s00534-002-0728-4

DO - 10.1007/s00534-002-0728-4

M3 - Article

C2 - 14505151

AN - SCOPUS:0141702081

VL - 10

SP - 168

EP - 171

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 0944-1166

IS - 2

ER -